|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2000-11-7
|
|
pubmed:abstractText |
A new type of organic Ca2+ channel blocker, tamolarizine, was examined for its reversing effect on multidrug-resistant tumor cells. Tamolarizine synergistically potentiated the cytotoxicity of doxorubicin for doxorubicin-resistant K562 cells (K562/DXR) at a concentration of 0.1-10 microM, but had hardly any synergistic effects in the parental cell line (K562) at the same concentration. Moreover, tamolarizine inhibits the P-glycoprotein pump-efflux activity in a dose-related manner and reduces the expression of the immunoreactive P-glycoprotein in K562/DXR cells as evaluated by cytofluorimetric assay. These results indicate that tamolarizine reverses the multidrug-resistance phenotype through direct interaction with P-glycoprotein.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0021-5198
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
82
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
265-8
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10887958-Azides,
pubmed-meshheading:10887958-Calcium Channel Blockers,
pubmed-meshheading:10887958-Dihydropyridines,
pubmed-meshheading:10887958-Doxorubicin,
pubmed-meshheading:10887958-Drug Resistance, Multiple,
pubmed-meshheading:10887958-Humans,
pubmed-meshheading:10887958-K562 Cells,
pubmed-meshheading:10887958-P-Glycoprotein,
pubmed-meshheading:10887958-Piperazines,
pubmed-meshheading:10887958-Rhodamine 123
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Reversal of multidrug resistance in human leukemia K562 by tamolarizine, a novel calcium antagonist.
|
|
pubmed:affiliation |
Medical Information Department, Nippon Chemiphar Co., Ltd., Tokyo, Japan.
|
|
pubmed:publicationType |
Journal Article
|
